Skip to main content

Market Overview

Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC

Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
  • Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. 
  • According to data released at the European Society for Medical Oncology 2021 (ESMO21), Libtayo, used on top of platinum doublet chemotherapy, reduced the risk of death by 29% over chemo alone in patients with previously untreated, advanced non-small cell lung cancer (NSCLC).
  • The phase 3 Empower-Lung 3 trial included both squamous and nonsquamous NSCLC patients.
  • Libtayo-chemo hit a median overall survival (OS) of 22 months versus 13 months for the solo chemo group, with a median progression-free survival of 8 months.
  • The Libtayo combo posted a 43% response rate compared with 23% for chemo and a 16-month duration response versus 7 months for chemo. No new Libtayo safety signals were identified.
  • Exploratory analyses showed survival improvements across squamous and nonsquamous histologies and in patients with reduced daily functioning. 
  • In another exploratory analysis, the Libtayo combination helped delay patient-reported quality of life deterioration and pain symptoms.
  • Price Action: REGN stock closed 0.20% lower at $651.88, and SNY stock closed at 0.39% higher at $48.38 on Friday.
  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

Related Articles (REGN + SNY)

View Comments and Join the Discussion!

Posted-In: Briefs ESMO21 Non-Small Cell Lung Cancer Phase 3 TrialBiotech News Health Care General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at